Beretta Giovanni Luca, Zunino Franco
Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy.
Top Curr Chem. 2008;283:1-19. doi: 10.1007/128_2007_3.
On the basis of evidence that anthracyclines are DNA intercalating agents and DNA is the primary target,a large number of analogs and related intercalators have been developed. However, doxorubicin andclosely related anthracyclines still remain among the most effective antitumor agents. Multiple mechanismshave been proposed to explain their efficacy. They include inhibition of DNA-dependent functions, freeradical formation, and membrane interactions. The primary mechanism of action is now ascribed to drug interferencewith the function of DNA topoisomerase II. The stabilization of the topoisomerase-mediated cleavablecomplex results in a specific type of DNA damage (i.e., double-strand protein-associated DNA breaks).The drug-stabilized cleavable complex is a potentially reversible molecular event and its persistence,as a consequence of strong DNA binding, may be recognized as an apoptotic stimulus. Indirect evidencesupports the notion that the bioreductive processes of the quinone moiety generating the semiquinone radicalwith concomitant production of reactive oxygen species may contribute to the drug effects. The cellulardefense mechanisms and response to genotoxic/cytotoxic stress appear to be critical determinants of thetumor sensitivity to anthracyclines.
基于蒽环类药物是DNA嵌入剂且DNA是主要靶点这一证据,人们已开发出大量类似物及相关嵌入剂。然而,阿霉素及密切相关的蒽环类药物仍是最有效的抗肿瘤药物之一。已提出多种机制来解释它们的疗效。这些机制包括抑制依赖DNA的功能、自由基形成以及膜相互作用。现在认为主要作用机制是药物干扰DNA拓扑异构酶II的功能。拓扑异构酶介导的可裂解复合物的稳定导致一种特定类型的DNA损伤(即双链蛋白质相关的DNA断裂)。药物稳定的可裂解复合物是一个潜在可逆的分子事件,由于与DNA的强结合,其持续性可能被视为一种凋亡刺激。间接证据支持这样的观点,即醌部分产生半醌自由基并伴随产生活性氧的生物还原过程可能有助于药物发挥作用。细胞防御机制以及对基因毒性/细胞毒性应激的反应似乎是肿瘤对蒽环类药物敏感性的关键决定因素。